Browsing Tag
Theraflu
2 posts
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Haleon (HLN) Q1 2026 results: Can Sensodyne and parodontax offset weak cold and flu demand?
Haleon’s cold and flu drag is testing growth. Sensodyne, parodontax and margin discipline may decide whether HLN can regain momentum.